JP2005509004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509004A5 JP2005509004A5 JP2003543600A JP2003543600A JP2005509004A5 JP 2005509004 A5 JP2005509004 A5 JP 2005509004A5 JP 2003543600 A JP2003543600 A JP 2003543600A JP 2003543600 A JP2003543600 A JP 2003543600A JP 2005509004 A5 JP2005509004 A5 JP 2005509004A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- donor
- nitroso
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- 201000010099 disease Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 239000002840 nitric oxide donor Substances 0.000 claims 13
- 230000004872 arterial blood pressure Effects 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 5
- 108020003175 receptors Proteins 0.000 claims 5
- 210000001147 pulmonary artery Anatomy 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- 230000016160 smooth muscle contraction Effects 0.000 claims 3
- 208000037905 systemic hypertension Diseases 0.000 claims 3
- 208000005189 Embolism Diseases 0.000 claims 2
- 239000004395 L-leucine Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 229960003136 leucine Drugs 0.000 claims 2
- 102000006240 membrane receptors Human genes 0.000 claims 2
- 108020004084 membrane receptors Proteins 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000002460 smooth muscle Anatomy 0.000 claims 2
- QWPCKAAAWDCDCW-VKHMYHEASA-N (2s)-2-amino-4-nitrososulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCSN=O QWPCKAAAWDCDCW-VKHMYHEASA-N 0.000 claims 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 150000004006 C-nitroso compounds Chemical class 0.000 claims 1
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 claims 1
- QQZWEECEMNQSTG-UHFFFAOYSA-N Ethyl nitrite Chemical compound CCON=O QQZWEECEMNQSTG-UHFFFAOYSA-N 0.000 claims 1
- 150000004008 N-nitroso compounds Chemical class 0.000 claims 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims 1
- 239000000006 Nitroglycerin Substances 0.000 claims 1
- 150000004009 O-nitroso compounds Chemical class 0.000 claims 1
- 206010030184 Oesophageal spasm Diseases 0.000 claims 1
- 201000000660 Pyloric Stenosis Diseases 0.000 claims 1
- 206010057011 Rectal spasm Diseases 0.000 claims 1
- 108010001742 S-Nitrosoglutathione Proteins 0.000 claims 1
- 150000004007 S-nitroso compounds Chemical class 0.000 claims 1
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 claims 1
- UOHAKHBEJRPHQZ-VKHMYHEASA-N S-nitroso-L-cysteinylglycine Chemical compound O=NSC[C@H](N)C(=O)NCC(O)=O UOHAKHBEJRPHQZ-VKHMYHEASA-N 0.000 claims 1
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 claims 1
- 108010093594 S-nitrosoalbumin Proteins 0.000 claims 1
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000028922 artery disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 210000003617 erythrocyte membrane Anatomy 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229960003711 glyceryl trinitrate Drugs 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 claims 1
- 229960004027 molsidomine Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 150000002828 nitro derivatives Chemical class 0.000 claims 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 210000001187 pylorus Anatomy 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 229940083618 sodium nitroprusside Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/986,807 US6472390B1 (en) | 2001-11-13 | 2001-11-13 | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| US09/986,807 | 2001-11-13 | ||
| PCT/US2002/025937 WO2003041713A1 (en) | 2001-11-13 | 2002-08-26 | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009113076A Division JP2009167223A (ja) | 2001-11-13 | 2009-05-07 | 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005509004A JP2005509004A (ja) | 2005-04-07 |
| JP2005509004A5 true JP2005509004A5 (enExample) | 2006-01-05 |
| JP5259038B2 JP5259038B2 (ja) | 2013-08-07 |
Family
ID=25532762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003543600A Expired - Fee Related JP5259038B2 (ja) | 2001-11-13 | 2002-08-26 | 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用 |
| JP2009113076A Withdrawn JP2009167223A (ja) | 2001-11-13 | 2009-05-07 | 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009113076A Withdrawn JP2009167223A (ja) | 2001-11-13 | 2009-05-07 | 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6472390B1 (enExample) |
| EP (1) | EP1458397A4 (enExample) |
| JP (2) | JP5259038B2 (enExample) |
| AU (1) | AU2002313758B2 (enExample) |
| CA (1) | CA2467159C (enExample) |
| WO (1) | WO2003041713A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2794647A1 (fr) * | 1999-06-11 | 2000-12-15 | Centre Nat Rech Scient | Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules |
| US7516742B2 (en) | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
| US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
| US6432077B1 (en) | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
| US20040225275A1 (en) * | 2001-08-02 | 2004-11-11 | Reynolds James Dixon | Fetal physiology during maternal surgery or diagnosis |
| US6676855B2 (en) * | 2001-08-02 | 2004-01-13 | Duke University | Use of a blood-flow decrease preventing agent in conjunction with insufflating gas |
| GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
| US6627602B2 (en) * | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
| US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
| EP1514103A4 (en) * | 2002-05-29 | 2006-05-24 | Univ Duke | MEASUREMENT OF NITROGEN MONOXIDE IN HEMOTOXIC GASES, AND TREATMENT BASED ON THIS MEASURE |
| US7531133B2 (en) | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
| WO2005004884A2 (en) * | 2003-07-09 | 2005-01-20 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
| CA2542426A1 (en) * | 2003-10-22 | 2005-05-06 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in cells |
| US20070270350A1 (en) * | 2003-12-23 | 2007-11-22 | Musc Foundation For Research Development | Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions |
| WO2005079782A1 (en) * | 2004-02-17 | 2005-09-01 | Thiolex Development Corp. | N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction |
| CA2561141A1 (en) * | 2004-03-31 | 2005-11-17 | Nitromed, Inc. | Methods for treating blood disorders with nitric oxide donor compounds |
| FR2868314B1 (fr) * | 2004-04-05 | 2008-10-24 | Therabel Pharmaceuticals Ltd | Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables |
| MXPA06013111A (es) | 2004-05-11 | 2007-05-23 | Sensormedics Corp | Dosificacion intermitente de gas de oxido nitrico. |
| US8518457B2 (en) | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
| US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US8557300B2 (en) * | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
| EP2669269B1 (en) | 2005-05-27 | 2019-05-22 | The University of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
| AU2007217980A1 (en) * | 2006-02-17 | 2007-08-30 | Nitromed, Inc. | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| WO2007103534A2 (en) * | 2006-03-07 | 2007-09-13 | Nitrox, Llc | Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof |
| WO2007146311A2 (en) * | 2006-06-12 | 2007-12-21 | N30 Pharmaceuticals, Llc | Compositions and methods for protecting newborn lung development with ethyl nitrite |
| US8079998B2 (en) | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
| US20110003012A1 (en) * | 2007-09-10 | 2011-01-06 | Duke University | Treating patients with subarachnoid hemorrhage |
| US20090196930A1 (en) * | 2007-12-27 | 2009-08-06 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
| US20110104308A1 (en) * | 2008-05-09 | 2011-05-05 | Duke University | Treatment For Diseases Relying On Discovery That Thioredoxin Mediates Nitric Oxide |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| EP2467173B8 (en) | 2009-08-21 | 2019-06-19 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118819A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
| JP6251849B2 (ja) * | 2015-10-13 | 2017-12-20 | 学校法人慶應義塾 | 椎間板変性症、腰痛改善を処置するための医薬組成物、及び治療薬のスクリーニング方法 |
| WO2019073045A1 (en) | 2017-10-12 | 2019-04-18 | Bdd Berolina Drug Development Gmbh | USE OF DONORS OF NO |
| US20240226140A1 (en) * | 2023-01-09 | 2024-07-11 | Azulent, Llc | Nitric oxide and molecular hydrogen generating compositions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900719A (en) * | 1988-08-05 | 1990-02-13 | The Ohio State University | Nitrosothiols as hypotensive agents |
| US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
| DE69127756T2 (de) * | 1990-12-05 | 1998-02-05 | The General Hospital Corp., Charlestown, Mass. | Verwendung von no zur behandlung oder prävention der bronchokonstriktion |
| NZ249176A (en) * | 1992-02-07 | 1996-11-26 | Vasogen Inc | Method of increasing concentration of nitric oxide in blood using ozone and uv radiation |
| US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
| US5861168A (en) * | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| US5869539A (en) * | 1996-04-17 | 1999-02-09 | Board Of Regents, The University Of Texas System | Emulsions of perfluoro compounds as solvents for nitric oxide (NO) |
| EP0951292B1 (en) * | 1996-09-27 | 2007-04-04 | The Trustees of Columbia University in the City of New York | Treating an ischemic disorder and improving stroke outcome |
| FR2757864B1 (fr) * | 1996-12-30 | 1999-03-19 | Centre Nat Rech Scient | Anticorps reconnaissant specifiquement une proteine nitrosylee, leur procede de preparation, leur utilisation therapeutique et diagnostique |
| AU9596698A (en) * | 1997-10-15 | 1999-05-03 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| JPH11217330A (ja) * | 1998-01-30 | 1999-08-10 | Sumitomo Pharmaceut Co Ltd | 神経栄養因子分泌促進剤 |
| US6265420B1 (en) * | 1998-06-23 | 2001-07-24 | Medinox, Inc. | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide |
| US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
| US6314956B1 (en) * | 1999-09-08 | 2001-11-13 | Duke University | Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders |
-
2001
- 2001-11-13 US US09/986,807 patent/US6472390B1/en not_active Expired - Lifetime
-
2002
- 2002-08-26 EP EP02753472A patent/EP1458397A4/en not_active Withdrawn
- 2002-08-26 JP JP2003543600A patent/JP5259038B2/ja not_active Expired - Fee Related
- 2002-08-26 CA CA2467159A patent/CA2467159C/en not_active Expired - Fee Related
- 2002-08-26 WO PCT/US2002/025937 patent/WO2003041713A1/en not_active Ceased
- 2002-08-26 AU AU2002313758A patent/AU2002313758B2/en not_active Ceased
-
2009
- 2009-05-07 JP JP2009113076A patent/JP2009167223A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5259038B2 (ja) | 血圧または肺動脈圧を大きく低下させない一酸化窒素ドナーの治療的投薬量の使用 | |
| JP2007506773A (ja) | 線溶系の障害および血栓症の治療用のｐａｉ−１阻害剤としての、４−（フェニル−エチリデンアミノキシ−プロポキシ）−フェニル−酢酸誘導体および関連化合物 | |
| CN113396145A (zh) | Pfkfb3抑制剂及其用途 | |
| JP2019531320A5 (enExample) | ||
| CN109316601B (zh) | 药物组合物及其用途 | |
| MA30344B1 (fr) | Pyrazoles actifs sur la 11-beta-hsd-1 | |
| CN105120866A (zh) | 与毒性醛相关的疾病和治疗 | |
| JP2007524653A (ja) | 置換ナフチルベンゾチオフェン酸 | |
| JP2007506759A (ja) | Ｐａｉ−１阻害剤としての置換オキサジアゾリジンジオン | |
| JP2007506755A (ja) | 線溶系の障害および血栓症の治療用のｐａｉ−１阻害剤としての、（（（（１ｈ−インドール−３イル）メチリデン）アミノ）オキシ）酢酸誘導体およびその関連化合物 | |
| CN101969944B (zh) | 脂肪性肝病的治疗用医药组合物 | |
| IL178425A (en) | History of carboxylic acid, their preparation and pharmaceutical preparations containing them | |
| TW201609081A (zh) | 治療肝臟病症之方法 | |
| JP5394933B2 (ja) | 眼圧降下剤として有用なチオフェン誘導体 | |
| AU2020376223B2 (en) | Combination therapy having antioxydant properties | |
| JP5253174B2 (ja) | Ｎ−フェニルオキサミド酸誘導体 | |
| JPH0430955B2 (enExample) | ||
| CN1250209C (zh) | 20－羟基二十碳四烯酸合成酶抑制剂 | |
| Jian et al. | Influence of aging and hemorrhage injury on Sirt1 expression: possible role of myc-Sirt1 regulation in mitochondrial function | |
| JPWO2022071578A5 (enExample) | ||
| CN1652774A (zh) | 缬沙坦或其代谢物用于抑制血小板凝集的用途 | |
| AR050358A1 (es) | Composiciones capaces de inhibir especies reactivas de oxigeno y carbonilo | |
| JPH02124869A (ja) | ロイコトリエン拮抗剤のエステルプロドラッグ | |
| WO2023166039A1 (en) | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | |
| JPS62223159A (ja) | （ｎ−置換フエニル）不飽和脂肪酸アミド誘導体、それらの製造方法及びそれらを有効成分として含有する５−リポキシゲナ−ゼ阻害剤 |